|

Glofitamab/Obinutuzumab Clinical Trials

2 actively recruiting trials across 1 location

▲ +1 trial since May 2026

Pipeline

Phase 2: 1Phase 1/2: 1

Top Sponsors

  • Liling Zhang1
  • Bristol-Myers Squibb1

Indications

  • Cancer2
  • Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)1
  • Relapsed/Refractory Non-Hodgkin Lymphoma1
  • Lymphoma1

Other1 trial

Hypofractionation Radiotherapy in Combination With Glofitamab in Relapsed/Refractory Diffuse B-cell Lymphoma With Baseline High Tumor Burden
Phase 2

Phoenix, Arizona1 trial

A Study to Assess BMS-986458 Alone and in Combination With Anti-lymphoma Agents in Relapsed/Refractory Non-Hodgkin Lymphomas

Mayo Clinic in Arizona - Phoenix

Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.